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Short title: Visceral, epicardial and/or intrathoracic fat? 
 
  
Abstract 
Objective  Previous studies have highlighted the associations between abdominal, cardiac 
or total fat accumulation and cardiovascular disease.  The aim of this study was to investigate 
the impact of different ectopic fat depots on measurements of metabolic dysfunction and 
cardiovascular disease risk. 
Methods  Using magnetic resonance imaging in 113 subjects, we measured abdominal 
(visceral and subcutaneous) and cardiac (epicardial and extra-pericardial) fat depots and 
examined their association with overall (BMI) and abdominal obesity (waist circumference), 
dyslipidaemia (triglycerides, total and HDL cholesterol), glucose tolerance (by an oral glucose 
tolerance test) and insulin sensitivity, blood pressure and 10-year coronary heart disease risk by 
Framingham score.  
Results  Fat accumulation was proportional to the degree of obesity, with body fat ranging 
from 14 to 33 kg, visceral fat from 0.8 to 1.8 kg and cardiac fat from 134 to 236 g. Most cardiac 
fat (70% on average) was extra-pericardial, with a wide variability for both cardiac depots 
(epicardial: 172–2008 mm2; extra-pericardial: 100–5056 mm2). Only visceral and extra-
pericardial fat, but not epicardial or subcutaneous fat, could discriminate between subjects with 
three or more factors of the metabolic syndrome or medium-to-high coronary heart disease risk 
score.  Controlling for gender and BMI by multivariable analysis, the best marker of reduced 
insulin sensitivity was visceral fat (partial r = –0.35); extra-pericardial fat was the closest 
associate of increased blood pressure (partial r = 0.26) and both extra-pericardial and visceral fat 
clustered with hypertriglyceridaemia (partial r = 0.29 and 0.24; both P < 0.02).  
  
Conclusion  Increased epicardial fat does not necessarily translate into presence or 
prediction of disease. In contrast, increased deposition of visceral abdominal and extra-
pericardial mediastinal fat are both associated with an enhanced cardiovascular disease risk 
profile.   
 
Keywords  epicardial, insulin resistance, intrathoracic fat, magnetic resonance imaging, 
metabolic syndrome, visceral fat 
 
Introduction 
 
Fat accumulates mainly in subcutaneous depots, but sizeable amounts of adipose tissue are 
also deposited in the abdomen (between and within organs), in the thorax (as epicardial, 
mediastinal and/or intramyocardial fat), in the pancreas and in skeletal muscle [1].  Although it is 
recognized that intracellular accumulation of fat is associated with organ dysfunction (i.e. 
lipotoxicity) [2], it is not feasible to measure it routinely as its measurement requires 
sophisticated techniques (i.e. high-field magnetic resonance spectroscopy or tissue biopsies).  
Other major sites of fat accumulation, such as visceral and cardiac depots, have been evaluated 
as markers of disease as their measurement is more practicable.  Visceral fat has been related to 
both metabolic and cardiovascular dysfunction [3,4].  Cardiac fat is now recognized as a new 
cardiometabolic risk marker, as it is associated with increased insulin resistance, cardiovascular 
risk factors, visceral fat and, in general, with the metabolic syndrome [5,6].  In the 
supradiaphragmatic region, fat is deposited in the intrathoracic space (extra-pericardial adipose 
tissue or mediastinal fat), around the myocardium (epicardial adipose tissue) and as 
intramyocardial fat.  Most of the research has focused on epicardial fat, which, given its location, 
  
is supposed to have a metabolic role.  Studies in animals [7] and in autoptic human hearts [8] 
have shown the importance of epicardial fat accumulation, but the interest in this fat depot has 
risen in recent years as new imaging techniques have become available.  Epicardial fat 
constitutes approximately 30% of intrathoracic fat, the majority being present as extra-
pericardial fat.  However, it is not always simple to distinguish epicardial from extra-pericardial 
fat, especially in non-obese subjects, and the sum of epicardial and extra-pericardial fat has 
frequently been considered [6,9].  We and others have shown that extra-pericardial fat strongly 
correlates with obesity, increased visceral fat and insulin resistance similarly to visceral fat 
[6,10–12].  
The question of whether these fat depots have similar clinical relevance as markers of 
metabolic dysfunction and cardiovascular disease risk has not been previously addressed.  
Therefore, in the present work, we set forth to assess the relationship between cardiac (both 
extra-pericardial and epicardial) fat and visceral fat accumulation and markers of coronary heart 
disease risk (lipid profile, blood pressure, insulin sensitivity and glucose tolerance) in a large 
group of subjects, including patients with Type 2 diabetes. 
 
Materials and methods 
Subjects 
From our diabetes screening clinic, we recruited 113 individuals undergoing oral glucose 
tolerance testing who agreed to magnetic resonance imaging examination of body fat distribution 
and quantitation.  The subjects (94 men and 19 women) had a mean age of 52 years and a BMI 
ranging from 18 to 40 kg/m2. Twenty-one individuals had Type 2 diabetes (fasting plasma 
glucose ≥ 7.0 mmol/l or a 2-h plasma glucose of ≥ 11.1 mmol/l), 13 of whom were newly 
  
diagnosed.  The study protocol was approved by the local ethics committee and all subjects gave 
their informed consent to participate.  
Anthropometric measurements 
We measured weight (to the nearest 0.1 kg) and height (to the nearest 0.5 cm) and waist–hip 
ratio while the subjects were fasting and wearing only their undergarments.  After a 30-min 
acclimation period, systolic, diastolic and mean blood pressure (calculated as diastolic blood 
pressure plus one third of the pulse pressure) were measured three times to the nearest 2 mmHg 
in the sitting position using a mercury sphygmomanometer and appropriately sized cuffs and 
then averaged.  The 75-g oral glucose tolerance test was carried out in the morning (08.00 h) 
after a 10- to 12-h overnight fast and blood samples were collected every 30 min for 2 h for the 
measurement of plasma glucose and insulin concentrations.  Eleven subjects without diabetes did 
not have an oral glucose tolerance test. 
Magnetic resonance imaging study 
Magnetic resonance imaging acquisition of the heart was carried out using a standardized 
protocol.  Cardiac coil and electrocardiograph triggering were used for the sequences; during the 
acquisition time, patients were holding their breath (10–12 s).  Cardiac adipose tissue scans were 
obtained by fast-spin echo T1-weighted sequences with oblique axial orientation, for a correct 
study of horizontal long axes of the heart [13] (echo time 42 ms; echo train length 23; bandwidth 
62.50; slice thickness 8 mm; slice gap 0 mm; field of view 38 cm; matrix 288 × 224 ; phase field 
of view 0.75; number of excitations 1; trigger delay = minimum; 8-mm thick section with 0-mm 
intersection gap, field of view and a 256 × 256 matrix).  Epicardial fat was defined as any 
adipose tissue located within the pericardial sac [11,12].  Extra-pericardial and epicardial fat 
areas were measured in a four-chamber view during the diastolic phase with the use of an in-
house semi-automatic program to determine the margin of fat around the heart, identifying 
  
region of interest and measuring the number of pixels, as previously described [12].  Two fat 
depots could be easily distinguished: (1) epicardial adipose tissue, the fat concentrated in the 
atrioventricular and interventricular grooves, along the major branches of the coronary arteries 
and, to a lesser extent, around the atria, over the free wall of the right ventricle and over the apex 
of the left ventricle; (2) extra-pericardial adipose tissue, the fat situated on the external surface of 
the parietal pericardium within the mediastinum, also termed intrathoracic fat. 
To test whether fat area was a good indicator of cardiac fat mass, in a separate group of 
normal subjects (n = 20) we quantified cardiac fat by acquiring all images in the short axis view 
that covered the heart from the apex of the ventricula to the top of the atria.  For each slice we 
quantified area and volume (calculated by multiplying each area by the thickness, i.e. 8 mm, with 
no gap between images).  Weight of cardiac fat was then obtained by multiplying the volume 
(mm3) by 0.92, which corresponds to cardiac fat density in g/kg [12].  Average fat area was 
2656 mm2; average fat volume was 22 586 mm3, corresponding to a cardiac fat mass of 208 g.  A 
strong linear relationship was found between cardiac fat mass and area measured in a four-
chamber view (r2 = 0.87, P < 0.0001), thus allowing the definition of a factor to calculate cardiac 
adipose tissue mass from area measurements (0.076 g/mm2). 
Abdominal visceral and subcutaneous fat depots were measured using imaging procedures 
that have been published previously [12,14].  Briefly, images were acquired on a GE Signa 
Excite HD 1.5T scanner (slew rate: maximum 150 T m–1 s–1) that operates with a 50-mT/m 
gradient using a body coil.  Thirty-two transverse, T1-weighted 256 × 256 images (repetition 
time = 135, echo time = 4.2, flip angle = 90°, field of view = 50 cm, pixel size 
1.875 × 1.875 mm) centred through the space between L4 and L5 were acquired in breath hold 
with a slice thickness of 5 mm with no overlap.  The subcutaneous fat area was analysed by 
automatic detection of the region of interest using an ad hoc developed software [14] and by 
  
counting the number of pixels between the outer and inner margins of subcutaneous adipose 
tissue.  The visceral (intra-abdominal) fat area was determined with the use of histograms 
specific to the visceral regions [14].  A factor of 0.92 was used to convert adipose tissue volume 
into adipose tissue mass [12].  
Analytical determinations 
Plasma glucose was measured by the glucose oxidase reaction (Beckman Glucose Analyzer; 
Beckman, Fullerton, CA, USA).  Plasma insulin concentrations were measured by 
radioimmunoassay using specific kits (Linco Research, St Louis, MO, USA).  
Calculations and statistical analysis 
Cardiovascular risk factors were defined as a systolic blood pressure > 130 mmHg or a 
distolic blood pressure > 85 mmHg, a waist circumference > 94 cm in men and > 80 cm in 
women, a serum triglyceride concentration > 1.7 mmol/l, an HDL cholesterol concentration 
< 1.0 mmol/l in men and < 1.3 mmol/l in women, and a fasting plasma glucose > 5.6 mmol/l 
[13].  An individual 10-year coronary heart disease risk was estimated using the Framingham 
Heart Study prediction score [15].  Insulin sensitivity was calculated as the oral glucose insulin 
sensitivity (OGIS) index, which equals the average metabolic clearance rate of glucose during 
the oral glucose tolerance test and has been validated against the euglycaemic insulin clamp 
technique [16]. 
Data are given as the mean ± SEM.  Data with a skewed distribution (i.e. plasma triglyceride, 
cholesterol and insulin concentrations) are given as median and interquartile range and were log-
transformed for use in statistical analysis.  Differences between group mean values were 
evaluated using the t-test or Mann–Whitney U-test for normally and non-normally distributed 
variables, respectively.  Correlations were calculated using Spearman coefficient.  The 
independent association of visceral and cardiac fat accumulation with blood pressure, 
  
triglyceride concentration and insulin sensitivity was evaluated by multiple and stepwise 
regression analysis adjusted for gender and BMI. 
 
Results 
 
Quantification of fat depots 
All four fat depots, visceral, subcutaneous, epicardial and extra-pericardial fat, showed a 
wide variability (Table 1).  On average, visceral fat made up ~30% of abdominal fat, while 
epicardial fat amounted to ~34% of intrathoracic fat.  All fat depots were increased in proportion 
to degree of obesity (Fig. 1).  Total body fat mass was associated with increased visceral fat 
(r = 0.48), subcutaneous fat (r = 0.89), epicardial fat (r = 0.32), and extra-pericardial fat 
(r = 0.37, all P < 0.002).  Both epicardial and extra-pericardial fat also correlated significantly 
with BMI (r = 0.34 and 0.43, P < 0.0002), waist circumference (r = 0.41 and 0.53, P < 0.0001), 
visceral fat (r = 0.34 and 0.58, P < 0.0007) and subcutaneous fat (r = 0.34 and 0.32, P < 0.002).  
Men had more extra-pericardial fat and visceral fat than women (extra-pericardial fat 1880 ± 96 
vs. 1154 ± 153 mm2, P < 0.002; visceral fat 1.44 ± 0.08 vs. 1.03 ± 0.19 kg, P = 0.04), but similar 
epicardial fat (818 ± 35 vs. 727 ± 93 mm2, P = not significant), for similar BMI and total fat 
mass. 
Relation of fat depots to glucose tolerance and insulin resistance 
No difference was found in epicardial, extra-pericardial, intrathoracic or abdominal 
subcutaneous fat between subjects with normal glucose tolerance (n = 49), impaired glucose 
tolerance (n = 32) and diabetes [n = 21 (of whom 13 had newly diagnosed diabetes)].  In 
contrast, visceral fat was higher in subjects with impaired glucose tolerance and Type 2 diabetes 
compared with those with normal glucose tolerance (normal glucose tolerance 1.16 ± 0.08, 
  
impaired glucose tolerance 1.55 ± 0.13, Type 2 diabetes 1.76 ± 0.28 kg; P < 0.05 after correction 
for gender).  
The insulin sensitivity index was inversely associated with visceral fat (r = –0.62, 
P < 0.0001), subcutaneous fat (r = –0.46, P < 0.0001) and extra-pericardial fat (r = –0.46, 
P < 0.0001), but not with epicardial fat.  
Relation of fat depots to cardiovascular disease risk 
When subjects were grouped according to the presence of factors of the metabolic syndrome 
[none (n = 13); one (n = 26); two (n = 26); three or more (n = 48)], visceral, extra-pericardial and 
intrathoracic fat, but not subcutaneous or epicardial fat, were significantly associated with ≥ 3 
factors (Fig. 2).  In subjects with increased blood pressure (systolic blood pressure > 140 mmHg 
and/or diastolic blood pressure > 90 mmHg), fat was increased as visceral fat (1.3 ± 0.1 vs. 
1.6 ± 0.1 kg, P = 0.04) and extra-pericardial fat (1579 ± 88 vs. 2178 ± 204 mm2, P = 0.002), but 
no significant difference was observed in subcutaneous fat (3.1 ± 0.2 vs. 3.3 ± 0.2 kg, P = 0.40) 
or epicardial fat (800 ± 39 vs. 814 ± 64 mm2, P = 0.86). Ten-year risk for coronary heart disease 
was calculated using the Framingham score.  In univariate analysis, visceral, extra-pericardial 
and total intrathoracic fat were each significantly associated with a high 10-year coronary heart 
disease risk, while no association was found for epicardial or subcutaneous fat (Fig. 3). The same 
relationships were obtained when only male subjects were considered. 
Cardiac and visceral fat as marker of cardiometabolic risk 
In a stepwise multiple regression model adjusting for gender and BMI, we evaluated the 
impact of fat accumulation (i.e. visceral, subcutaneous, epicardial and extra-pericardial fat) on 
blood pressure, plasma triglycerides and insulin resistance.  Blood pressure (both systolic and 
diastolic) was significantly associated only with extra-pericardial fat (partial r = 0.26, P < 0.02).  
Triglyceride concentration was best associated with both visceral fat (partial r = 0.24, P < 0.02) 
  
and extra-pericardial fat (partial r = 0.29, P < 0.007), but not epicardial fat.  Insulin sensitivity 
was associated only by visceral fat (partial r = –0.35, P = 0.002).  Ten-year coronary heart 
disease risk was significantly associated only with visceral fat (partial r = 0.38, P < 0.0003). 
 
Discussion 
General obesity, and in particular ectopic fat accumulation, is associated with an increased 
incidence of cardiovascular disease, mainly because of the release of adipokines that impair 
insulin signalling and promote endothelial dysfunction, adhesion of monocytes and formation of 
foam cells in the arterial wall [17].  As expected, we found that ectopic fat accumulates in 
proportion to the degree of obesity, mainly as visceral fat (0.8–1.8 kg for a total body fat of 14–
33 kg), but also, to a lesser extent, as cardiac fat (134–236 g).  Moreover, there was a sizeable 
effect of gender, with men accumulating more extra-pericardial and visceral fat than women 
despite similar BMI and total fat mass.  When examining which ectopic fat depot was clinically 
relevant as a marker of metabolic dysfunction and coronary heart disease risk, we found that 
elevated triglyceride concentrations were associated with increased visceral and extra-pericardial 
fat, but not with epicardial or subcutaneous fat, while glucose intolerance (either impaired 
glucose tolerance or Type 2 diabetes) was associated with increased visceral fat.  Only visceral 
and extra-pericardial fat were significantly elevated in subjects with increased blood pressure 
and/or high 10-year coronary heart disease risk (calculated using the Framingham score).  
By accounting for gender and overall adiposity (as BMI) in a multivariable analysis, we 
found that visceral fat was the best marker of reduced insulin sensitivity, extra-pericardial fat 
was the closest associate of increased blood pressure and both extra-pericardial and visceral fat 
clustered with hypertriglyceridemia.  Only visceral, total intrathoracic and extra-pericardial fat, 
but not epicardial or subcutaneous fat, could discriminate subjects with more than three factors 
  
of the metabolic syndrome or those with a medium to high coronary heart disease risk score 
(Figs 1 and 2).  
Despite its small amount, cardiac fat, in particular epicardial fat, has been proposed as an 
important cardiovascular risk factor because of its location [5,11].  The clinical significance of 
epicardial fat is posited by the fact that this tissue has an increased expression of inflammatory 
genes [6,18–21] and is perfused by the coronary vasculature [8].  However, a cause–effect 
relationship has not been proven [22].  Moreover, most of the studies linking epicardial fat with 
risk have been conducted in subjects with severe cardiac disease—often those undergoing 
cardiac surgery—as recently pointed out by Sacks [22].  This could explain why the association 
between epicardial fat and cardiovascular disease risk factors did not emerge in the present 
series. 
The impact of increased extra-pericardial fat (also named mediastinal or intrathoracic fat) is 
less known.  Even in studies where extra-pericardial fat was quantified, it was not considered as 
important as epicardial fat.  Only few studies have quantified extra-pericardial fat by magnetic 
resonance imaging or computed tomography.  Studies using ultrasound measured only epicardial 
thickness, probably because the acoustic window does not allow measurements as accurate and 
reproducible as those obtained by magnetic resonance imaging or computed tomography [23].  
However, despite the fact that extra-pericardial fat is not in local anatomical contact with the 
coronary arteries, it constitutes the majority of cardiac fat accumulation (~70% on average), 
making it unlikely that it is just an inert compartment.  In fact, recent studies from the 
Framingham cohort have found epicardial fat to be associated with coronary artery calcification, 
whereas extra-pericardial fat was associated with abdominal aortic calcification [11] and was 
better correlated with metabolic risk factors than epicardial fat, equalling visceral fat in 
predictive power.  Moreover, the correlation between cardiac fat and measures of left ventricular 
  
structure and function was stronger for extra-pericardial than epicardial fat in women (but was 
lost when adjusting for body weight or visceral fat), while in men only intrathoracic fat remained 
correlated with left ventricular end diastolic volume [24].  In our subjects, extra-pericardial, but 
not epicardial, fat was associated with insulin resistance, increased blood pressure and 10-year 
coronary heart disease risk.  Extra-pericardial fat also correlated with visceral fat, confirming 
previous results [6,11,12].  This is in line with previous studies using computed tomography and 
magnetic resonance imaging, which measured both epicardial and extra-pericardial fat, and 
showed an association between cardiac fat, insulin resistance and blood pressure [12,25].  
In conclusion, fat accumulates everywhere as body weight increases; the largest ectopic 
depots are visceral fat in the abdominal area and extra-pericardial fat in the intrathoracic area.  
Our results reconsider the role of epicardial fat as an important marker of cardiometabolic risk. 
Visceral fat was the best marker of altered cardiovascular disease risk profile and increased 
extra-pericardial fat was associated with coronary heart diseasea risk.  In this cohort, epicardial 
fat did not show an independent association with measurements of metabolic dysfunction or 
coronary heart disease risk, indicating that increased epicardial fat  alone does not necessarily 
translate into presence or prediction of disease.  
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Table 1  Clinical and metabolic characteristics 
 
Mean or median Range 
 
Men/women 94/19  
Lean/overweight/obese 35/51/27  
No diabetes/Type 2 diabetes 92/21  
Age (years) 52 ± 1 18–74 
BMI (kg/m2) 27.3 ± 0.4 18–40 
Waist circumference (cm) 95 ± 1 68–125 
Epicardial fat area (mm2) 802 ± 33 172–2008 
Extra-pericardial fat area (mm2) 1759 ± 87 100–5056 
Epicardial/intrathoracic fat (%) 34 ± 1 10–83 
Epicardial fat mass (g) 61 ± 2 13–153 
Extra-pericardial fat mass (g) 134 ± 6 8–384 
Intrathoracic fat (g) 195 ± 8 32–471 
Subcutaneous fat mass (kg) 3.1 ± 0.2 0.6–8.3 
Visceral fat mass (kg)  1.40 ± 0.08 0.02–4.47 
Visceral fat/subcutaneous fat 0.48 ± 0.03 0.03–1.41 
Total body fat (kg)  22.0 ± 0.8 7.6–53.4 
Triglycerides (mmol/l) 1.0 (0.7) 0.3–4.0 
Total cholesterol (mmol/l) 4.9 (1.3) 1.7–7.7 
HDL cholesterol (mmol/l) 1.1 (0.4) 0.5–2.6 
LDL cholesterol (mmol/l) 3.2 (1.1) 0.9–5.7 
Systolic blood pressure (mmHg) 131 ± 2 100–220 
Diastolic blood pressure (mmHg) 76 ± 1 46–108 
Fasting glucose (mmol/l) 5.8 ± 0.1 4.3–10.8 
Fasting insulin (pmol/l) 70 (48) 16–358 
Insulin sensitivity (ml.min–1.kg–1) 8.9 ± 0.2 5.4–13.8 
 
  
 
Figure 1  Cardiac (epicardial, extra-pericardial and intrathoracic fat area) and abdominal 
(visceral and subcutaneous mass) fat distribution by degree of obesity (*P < 0.05 vs. lean in each 
group). NS, not significant.   
 
Figure 2  Cardiac (epicardial, extra-pericardial and intrathoracic fat area) and abdominal 
(visceral and subcutaneous mass) fat distribution in relation to the number of factors associated 
with the metabolic syndrome (*P < 0.05 vs. zero factors in each subgroup). 
 
Figure 3  Cardiac (epicardial, extra-pericardial and intrathoracic) fat area in relation to 10-
year coronary heart disease (CHD) risk calculated from the Framingham score (*P < 0.05 vs. 
low risk).  
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Figure 1 
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Figure 2 
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Figure 3 
